SCHEMBL1746715

SCHEMBL1746715

CCCCCCN(Cc1ccc(COc2ccc(CCC(=O)O)cc2)cc1)c1nc(-c2ccccc2)cs1

nearest known ligand 0.53

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 6/20 0.53
FFAR1 O14842 5/20 0.51
ATP4A P20648 6/20 0.47
ATP4B P51164 6/20 0.47
PPARG P37231 3/20 0.47
FFAR4 Q5NUL3 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
PPARA Q07869 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1745053 0.93 FFAR1 (0.53) PPARDFFAR1ATP4AATP4BPPARG
SCHEMBL1745386 0.93 ATP4A (0.45) PPARDFFAR1ATP4AATP4BMEN1
SCHEMBL3911382 0.91 PPARD (0.58) PPARDFFAR1PPARGFFAR4MEN1
SCHEMBL3913893 0.91 ATP4A (0.52) PPARDFFAR1ATP4AATP4BPPARG
SCHEMBL3912223 0.90 PPARD (0.57) PPARDFFAR1PPARGFFAR4MEN1
SCHEMBL3920624 0.90 PPARD (0.57) PPARDFFAR1PPARGFFAR4MEN1
SCHEMBL3921961 0.90 PPARD (0.54) PPARDFFAR1PPARGFFAR4MEN1
SCHEMBL1746802 0.89 FFAR1 (0.55) PPARDFFAR1FFAR4MEN1KMT2A
SCHEMBL3920075 0.89 PPARD (0.52) PPARDFFAR1PPARGFFAR4MEN1
SCHEMBL3914638 0.88 FFAR1 (0.58) PPARDFFAR1FFAR4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR PPARD 326/4885FFAR1 33/4885ATP4A 655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.